Title: Non-Destructive Quality Assessment of Therapeutic Cells: Toward Utilizing Data and AI in the Cell Manufacturing Industry
Speaker: Ryuji Kato, Associate Professor, Department of Drug Discovery Biology, Division of Fundamental Drug Discovery, Graduate School of Pharmaceutical Sciences, Nagoya University
Abstract: Recent advances in cell science have enabled the emergence of regenerative medicine as a new therapeutic approach for treating diseases and tissue damage that conventional pharmaceuticals could never cure. Here, cells obtained from patients are mass-cultured outside the body and used as \u201cliving medicine\u201d for treatment. Consequently, the demand for \u201clarge quantities of therapeutic cells\u201d is currently growing worldwide. However, the reality is that mass production of cells with pharmaceutical-grade quality control remains challenging. This is because cell culture has largely developed relying on \u201cmanual labor\u201d and the \u201cexpert intuition\u201d of skilled practitioners. The advancement of regenerative medicine is said to depend on the maturation of this cell manufacturing industry. Most industrial products began as handmade goods, later evolving through technological advances toward mechanization and automation to reach a broader audience. Similarly, the field of regenerative medicine is now challenging itself to accelerate the industrialization of cell culture and manufacturing by leveraging data and AI more extensively. This presentation will explore the potential and challenges of utilizing data and AI within this cell manufacturing domain.<\/p>\n\n\n\n
23rd January, 2026\uff08Fri,\uff0918:00\uff5e20:00<\/p>\n<\/dd>\n\n\n\n
Held online<\/p>\n<\/dd>\n\n\n\n
Co-organizer (HRAM The Japan Society for Industrial and Applied Mathematics, D-DRIVE National Network)<\/p>\n<\/dd>\n\n\n\n
Free\uff08Advance registration required\uff09<\/p>\n\n\n\n